Day One Biopharmaceuticals, Inc.

Company Overview

Business Model: Day One Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing targeted therapies for life-threatening diseases across all age groups. The company employs a "search & development" strategy to identify, acquire, and advance potential best- or first-in-class programs, aiming to introduce new medicines for both children and adults. Its primary revenue generation mechanism is the commercialization of its approved product, OJEMDA, in the United States, and through licensing agreements for ex-U.S. commercialization.

Market Position: Day One Biopharmaceuticals, Inc. has established a leadership position in targeted oncology therapeutics, particularly leveraging its expertise in pediatric drug development. Its first commercial product, OJEMDA (tovorafenib), is the only systemic therapy for pediatric low-grade glioma (pLGG) offering once-weekly dosing, with or without food, as a tablet or oral suspension. The company targets genomically-defined cancers, a rapidly evolving area, and aims to address high unmet medical needs in rare diseases. OJEMDA was added to the National Comprehensive Cancer Network (NCCN) adult glioma treatment guidelines as a category 2a recommended treatment option for recurrent or progressive BRAF-altered disease in June 2025.

Recent Strategic Developments:

• April 2024: FDA approved OJEMDA (tovorafenib) for patients 6 months and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, under accelerated approval. The company subsequently launched OJEMDA in the U.S. and received and sold a rare pediatric disease priority review voucher for $108.0 million.
• July 2024: Entered into an exclusive license agreement with Ipsen Pharma SAS to commercialize tovorafenib in all territories outside the United States. Day One Biopharmaceuticals, Inc. received an upfront license fee of $70.8 million and Ipsen Biopharmaceuticals, Inc. purchased 2,341,495 shares of common stock for $40.0 million. Day One Biopharmaceuticals, Inc. is eligible for up to approximately $375.0 million in additional commercial launch and sales-based milestones, plus tiered, double-digit royalties starting at mid-teens percentage of annual net sales.
• June 2024: Entered into a license agreement with MabCare Therapeutics for an exclusive worldwide license (excluding Greater China) to develop, manufacture, and commercialize DAY301, a novel Antibody Drug Conjugate (ADC) targeting protein-tyrosine kinase 7 (PTK7). Day One Biopharmaceuticals, Inc. made an upfront payment of $55.0 million in July 2024 and is eligible for up to $1,132.0 million in additional milestone payments plus low-to-mid single-digit royalties on net sales outside of Greater China.
• January 2025: FDA approved FoundationOne CDx as a companion diagnostic for OJEMDA.
• November 2025: Entered into an Agreement and Plan of Merger to acquire Mersana Therapeutics, Inc. for $25.00 net per share in cash plus one contingent value right (CVR) per share (up to $30.25 per share in cash upon milestones). The transaction closed on January 6, 2026, adding Emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC for adenoid cystic carcinoma (ACC), to the pipeline.

Geographic Footprint: Day One Biopharmaceuticals, Inc. primarily operates and commercializes OJEMDA in the United States. Through its licensing agreement with Ipsen Pharma SAS, tovorafenib is being commercialized in all territories outside the United States. Clinical trials for tovorafenib (FIREFLY-2) are enrolling patients in the United States, Canada, Europe, Australia, South America, the Middle East, and Asia. For DAY301, the antibody and linker payload, as well as final drug product manufacturing, are conducted in China. The MabCare License Agreement grants worldwide rights excluding Greater China. All of the company's assets are located in the United States.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 89.1%
• Operating Margin: -80.8%
• Net Margin: -67.8%

Investment in Growth (2025):

• R&D Expenditure: $148.1 million (93.6% of revenue)
• Capital Expenditures: $0.3 million
• Strategic Investments:
  • XOMA (US) LLC milestone payments: $6.0 million
  • Mersana Therapeutics, Inc. acquisition: $128.8 million cash paid (subsequent event, January 2026)

Business Segment Analysis

Day One Biopharmaceuticals, Inc. views its operations and manages its business in one operating segment. However, it has a distinct product and product candidate pipeline.

OJEMDA (tovorafenib)

Financial Performance:

• Revenue: $155.4 million (+171.6% YoY from $57.2 million in 2024)
• Operating Margin: Not directly calculable for product alone, but contributes to overall company gross margin of 89.1%.
• Key Growth Drivers: U.S. commercial launch in May 2024 for relapsed or refractory pLGG; ongoing pivotal Phase 3 FIREFLY-2 trial as a front-line therapy in pLGG; NCCN guideline inclusion for adult glioma; ex-U.S. commercialization rights licensed to Ipsen Pharma SAS.

Product Portfolio:

• OJEMDA (tovorafenib): Oral, brain-penetrant, highly selective type II RAF kinase inhibitor. Approved by FDA in April 2024 for patients 6 months and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
• Formulations: Tablet and oral suspension, offering once-weekly dosing.
• Companion Diagnostic: FoundationOne CDx approved by FDA in January 2025.

Market Dynamics:

• Target Population: Pediatric low-grade glioma (pLGG) patients, specifically those with BRAF fusions/rearrangements or BRAF V600 mutations. Estimated addressable pool of recurrent, progressive, or refractory pLGG patients is 2,000-3,000 per year at steady state.
• Competitive Positioning: Positioned as the only systemic therapy for pLGG with once-weekly dosing. Competes with existing BRAF/MEK inhibitors (e.g., dabrafenib/trametinib for BRAF V600E pLGG ≥ 1 year old) and other targeted therapies, some used off-label or in investigator-initiated trials. Tovorafenib's mechanism (type II RAF inhibitor) broadens its potential application beyond V600 mutations.
• Clinical Data (FIREFLY-1, May 10, 2024 data cutoff):
  • Overall Response Rate (ORR): ~53% (38% partial response, 15% minor response) in 76 evaluable patients.
  • ORR in BRAF fusions/rearrangements: 53%.
  • ORR in BRAF V600 mutation: 50%.
  • Median Duration of Response: 18 months.
  • Median Time to Response: 5.4 months.
  • Safety profile consistent with approval, no new safety signals.
• Clinical Data (FIREFLY-1, June 6, 2025 data cutoff):
  • Updated median study duration: 40.6 months.
  • ORR: 53%.
  • Median Duration of Response: 19.4 months.
  • Median Time to Response: 5.4 months.
  • Median time-to-next-treatment: 42.6 months.
  • Treatment-free observation period: 39 patients, 77% treatment-free for ≥12 months.
  • No new safety signals; common Grade 3+ adverse events: decreased growth velocity, anemia, blood creatine phosphokinase increased, maculopapular rash, alanine aminotransferase increased.
• Ongoing Trials: Pivotal Phase 3 FIREFLY-2 trial (front-line pLGG, ages 6 months to 25 years) initiated June 2022, first patient dosed March 2023, enrollment expected to complete H1 2026.

Emiltatug ledadotin (Emi-Le; DAY501 or XMT-1660)

Financial Performance: No specific revenue or operating margin data available as it was acquired in January 2026. Key Growth Drivers: Potential first-in-class monotherapy for adenoid cystic carcinoma (ACC), an aggressive cancer with high unmet need. Early anti-tumor activity observed in Phase 1 study. Product Portfolio:

• Emi-Le: B7-H4-directed Antibody-Drug Conjugate (ADC) with a site-specific conjugated auristatin F-HPA microtubule inhibitor payload. Market Dynamics:
• Target Population: Patients with advanced solid tumors, with a focus on aggressive ACC where B7-H4 is highly expressed.
• Clinical Status: Currently in Phase 1 dose escalation and backfill study across multiple adult tumor types (breast, ovarian, endometrial, ACC). Day One Biopharmaceuticals, Inc. plans to present clinical data mid-2026.

DAY301

Financial Performance: No specific revenue or operating margin data available. Key Growth Drivers: Novel PTK7-targeted ADC with encouraging preclinical antitumor efficacy in a wide range of solid tumors. Product Portfolio:

• DAY301: PTK7-targeted ADC composed of a humanized anti-PTK7 monoclonal antibody conjugated with a topoisomerase I inhibitor (exatecan mesylate) via a cleavable linker. Market Dynamics:
• Target Population: Patients with advanced solid tumors known to have high PTK7 expression (e.g., ovarian, NSCLC, TNBC, SCLC, ESCC, CSCC, colorectal, esophageal adenocarcinoma).
• Clinical Status: Initiated Phase 1a/b dose-escalation and cohort expansion study. First cohort cleared in January 2025. Initial clinical data and program update planned for H2 2026.
• Competitive Positioning: A few other PTK7-targeted ADCs are in development, but one (PRO1107/GEN1107) was discontinued in September 2025.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None disclosed.
• Dividend Payments: Day One Biopharmaceuticals, Inc. has never declared or paid cash dividends and does not intend to in the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $197.1 million
• Total Debt: No long-term debt explicitly stated.
• Net Cash Position: $197.1 million (assuming no significant debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as no significant debt is disclosed.

Cash Flow Generation (Year Ended December 31, 2025):

• Operating Cash Flow: $(103.8) million (Net cash used in operating activities)
• Free Cash Flow: $(104.1) million (Operating Cash Flow of $(103.8) million minus Capital Expenditures of $0.3 million)
• Cash Conversion Metrics: Not explicitly detailed, but the company has incurred significant net losses since inception and expects continued losses.

Operational Excellence

Production & Service Model: Day One Biopharmaceuticals, Inc. does not own or operate manufacturing facilities. It relies on third-party contract manufacturing organizations (CMOs) for the manufacture of its product candidates for clinical testing and commercial use, as well as for packaging, labeling, storage, and distribution. This strategy aims for an efficient infrastructure, focusing internal resources on development.

Supply Chain Architecture: Key Suppliers & Partners:

• API & Drug Product Manufacturing (OJEMDA): STA Pharmaceutical Hong Kong Limited, Quotient Sciences – Philadelphia, LLC (drug manufacturing).
• Packaging & Serialization (OJEMDA): Experic, LLC and Sharp Packaging Services, LLC.
• DAY301 Manufacturing: Antibody, linker payload, and final drug product manufacturing are all conducted in China.
• Companion Diagnostics: Foundation Medicine, Inc. (for FoundationOne CDx).

Facility Network:

• Principal Executive Office: Brisbane, California (approximately 19,000 square feet of leased office space, lease expires January 2032).
• Manufacturing: Relies entirely on third-party CMOs globally, with some key suppliers in China.
• Research & Development: Not explicitly detailed beyond the general executive office space, implying R&D is managed internally but executed through CROs and other third parties.
• Distribution: Relies on specialty distributors and specialty pharmacies in the U.S. For ex-U.S., Ipsen Pharma SAS handles distribution.

Operational Metrics:

• Supply Chain Risk: Exposed to risks from single-source CMOs and raw material suppliers, particularly those in China, including geopolitical uncertainty, tariffs, and potential disruptions.
• Manufacturing Scale-up: Has not yet scaled up manufacturing for all product candidates and may need to do so for future supply needs.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales (U.S.): Utilizes an efficient sales organization with 18 representatives targeting approximately 200 accounts that treat over 90% of pLGG patients.
• Channel Partners (U.S.): Engages with managed care, government payers, hospital systems, specialty distributors, and specialty pharmacies to ensure effective distribution and coverage for OJEMDA.
• Channel Partners (Ex-U.S.): Licensed exclusive commercialization rights for tovorafenib to Ipsen Pharma SAS, leveraging their established teams and expertise in international markets.
• Digital Platforms: Acknowledges promotional sales approaches are rapidly moving to digital platforms.

Customer Portfolio: Enterprise Customers:

• Customer Concentration: For the year ended December 31, 2025, two individual customers accounted for 97.6% of total net product revenue (66.7% and 30.9% respectively). As of December 31, 2025, these two customers represented 94.6% of accounts receivable (67.4% and 27.2% respectively).
• Strategic Partnerships: Ipsen Pharma SAS for ex-U.S. commercialization of tovorafenib.

Geographic Revenue Distribution:

• United States: All net product revenues from OJEMDA sales are derived from the United States.
• Growth Markets: International commercialization of tovorafenib is managed by Ipsen Pharma SAS.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The field of targeted oncology, especially for genomically-defined cancers, is rapidly evolving. Pediatric oncology has unique advantages such as enriched responder populations and established regulatory paths for accelerated feedback. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Novartis: Dabrafenib (Tafinlar®) in combination with trametinib (Mekinist®) approved for adult and pediatric patients ≥ 6 years with unresectable/metastatic solid tumors with BRAF V600E mutation, including pLGG.
• Genentech: Vemurafenib (Zelboraf®), cobimetinib (Cotellic®).
• Pfizer: Encorafenib (Braftovi®), binimetinib (Mektovi®).
• AstraZeneca: Selumetinib (Koselugo®) for NF1-associated plexiform neurofibromas.
• SpringWorks Therapeutics: Mirdametinib (Gomekli®) for NF1-associated plexiform neurofibromas.
• Next-generation BRAF inhibitors in clinical development: Fore Biotherapeutics (plixorafenib), Black Diamond Therapeutics (BDTX-4933), Jazz Pharmaceuticals and Redx Pharma (JZP815), Erasca and Novartis (naporafenib), Nested Therapeutics (NST-628), Pfizer (PF-07799933).
• PTK7-targeted ADCs in clinical development: Sichuan Kelun Pharmaceutical Research Institute (SKB518), Eli Lilly and Company (LY4175408). (Profound Bio/Genmab's PRO1107/GEN1107 was discontinued).
• ACC treatments in development: Puxitatug samrotecan (AZD8205), sacituzumab govitecan, enfortumab vedotin (ADCs); Remix Therapeutics’ REM-422 (MYB mRNA degrader); Ascentage’s alrizomadlin (MDM2 inhibitor); AL101 (gamma-secretase inhibitor).

Emerging Competitive Threats: New entrants, disruptive technologies, alternative solutions, and off-label use of existing agents. The increasing focus on pediatric indications (e.g., RACE for Children Act) may intensify competition for eligible patients in clinical trials.

Competitive Response Strategy: Focus on developing first- or best-in-class medicines, leveraging unique expertise in pediatrics, deploying proven business development expertise to expand the targeted oncology pipeline, and evaluating collaborations to accelerate development and enhance commercial potential (e.g., Ipsen Pharma SAS for ex-U.S. commercialization).

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Limited Patient Subsets: Market opportunities for approved products may be limited to smaller, genomically-defined patient subsets, potentially smaller than estimated.
• Competition: Intense competition from pharmaceutical and biotechnology companies with greater resources, established market presence, and expertise. Competitors may develop safer, more effective, or less expensive products, or obtain regulatory approval more rapidly.
• Off-label Use: Approved products may compete with drugs prescribed off-label for the same indications.
• Pricing Pressure: Increasing governmental scrutiny over drug pricing and cost containment measures (e.g., IRA, state legislation) could reduce prices and reimbursement.
• Uncertainty in Pediatric Oncology: Evolving statutory requirements and regulatory standards for pediatric drug development, and competition for eligible patients in trials.
• Geopolitical Uncertainty: Supply chain disruptions, increased costs due to tariffs (especially from China), and political unrest could impact operations.

Technology Disruption:

• Rapidly Advancing Technologies: Risk that competitors' technological advances or products could render Day One Biopharmaceuticals, Inc.'s technologies or product candidates obsolete, less competitive, or uneconomical.
• Novel Approach Risk: The approach of developing targeted therapeutics for genomically-defined cancers is novel and may not always lead to additional approved or marketable products.

Customer Concentration:

• Revenue Dependency: Substantial portion of revenue from a limited number of customers (e.g., two customers accounted for 97.6% of net product revenue in 2025), posing risk if these customers reduce demand or are lost.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Manufacturing Reliance: Dependence on a limited number of third-party CMOs (some in China) for API, drug product, and packaging, increasing risk of production difficulties, supply disruptions, and quality issues.
• Single-Source Suppliers: Reliance on sole suppliers for certain raw materials, increasing vulnerability to capacity constraints, price increases, and disruptions.
• Geographic Concentration: Manufacturing in China exposes the company to economic sanctions, changes in government policies, and trade barriers.
• Scale-up Challenges: Potential difficulties in increasing manufacturing capacity for product candidates in a timely or cost-effective manner.

Capacity Constraints:

• Clinical Trial Enrollment: Difficulties in identifying and enrolling sufficient eligible patients for clinical trials, especially for orphan/rare diseases and pediatric populations, could delay or terminate development.
• Personnel: Inability to attract, retain, and motivate highly qualified managerial, scientific, medical, and commercial personnel in a competitive environment.

Financial & Regulatory Risks

Market & Financial Risks:

• Operating Losses: History of significant net losses and expectation of continued losses for the foreseeable future, with no guarantee of achieving or maintaining profitability.
• Capital Requirements: Need for substantial additional funding to finance operations, clinical development, and commercialization efforts, with no committed external sources.
• Dilution: Future equity financings could dilute existing stockholder ownership.
• Product Liability: Significant product liability risks inherent in development, testing, manufacturing, and commercialization, potentially leading to investigations, recalls, or substantial monetary awards.

Regulatory & Compliance Risks:

• Extensive Regulation: Pharmaceutical product development and commercialization are subject to extensive and complex regulation by FDA and foreign authorities.
• Clinical Trial Failure: High risk of failure in clinical trials due to design flaws, safety concerns, or inability to demonstrate efficacy, leading to delays or abandonment.
• Accelerated Approval Risks: Accelerated approval for OJEMDA requires post-marketing confirmatory studies; failure to conduct these diligently or confirm clinical benefit could lead to withdrawal of approval.
• Post-Approval Requirements: Ongoing compliance with cGMPs, advertising/promotion restrictions, adverse event reporting, and potential REMS or post-marketing studies.
• Foreign Approvals: No assurance of obtaining marketing authorizations in foreign jurisdictions, limiting market access.
• Healthcare Laws: Compliance with anti-kickback, fraud and abuse, transparency, and health privacy laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, ACA, IRA) is costly and violations could lead to significant penalties.
• Companion Diagnostic Approval: Dependence on successful development and approval of companion diagnostics for product candidates.
• FDA Disruptions: Potential delays in FDA review/approval due to staffing changes, government shutdowns, or policy shifts.

Geopolitical & External Risks

Geopolitical Exposure:

• International Operations: Expansion outside the U.S. requires compliance with diverse laws (e.g., FCPA, export controls, sanctions), increasing costs and potential limitations.
• Trade Relations: Tariffs and trade restrictions (e.g., U.S.-China) could increase costs and disrupt supply chains.
• Russia-Ukraine Conflict: Potential impact on intellectual property rights and operations in affected regions.

External Events:

• Natural Disasters/Pandemics: Operations concentrated in the San Francisco Bay Area are vulnerable to natural disasters (e.g., earthquakes). Global pandemics or other catastrophic events could disrupt business continuity.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• RAF Kinase Inhibition: OJEMDA (tovorafenib) is an oral, brain-penetrant, highly selective type II RAF kinase inhibitor, designed to inhibit both monomeric and dimeric RAF kinase, broadening its potential clinical application beyond BRAF V600-altered tumors.
• Antibody Drug Conjugates (ADCs):
  • B7-H4-directed ADC: Emiltatug ledadotin (Emi-Le) targets B7-H4, highly expressed in adenoid cystic carcinoma (ACC) and other cancers.
  • PTK7-targeted ADC: DAY301 targets PTK7, overexpressed in multiple adult cancers, using a topoisomerase I inhibitor payload.
• Innovation Pipeline: Focus on identifying, acquiring, and developing potential best- or first-in-class programs for genomically-defined cancers.

Intellectual Property Portfolio:

• Patent Strategy: Pursues multilayered patent protection covering compositions of matter, methods of use, and methods of manufacture for drug candidates. Aims to strengthen protection through additional filings.
• Patent Holdings (as of January 1, 2026):
  • Owned/Co-owned: Ten patent families.
    • Tovorafenib: Composition of matter and pharmaceutical compositions (U.S. patent to 2031, foreign to 2028; U.S. patent term extension applications filed, potentially to August 2036). Additional patents/applications for formulations, methods of use, and synthesis (expiring 2035-2044).
    • Emi-Le (post-Mersana acquisition): Payload and synthesis (U.S. and foreign to 2032). Emi-Le, intermediates, and synthesis (U.S. and foreign to 2041-2042). Methods of treating ACC (pending PCT to 2044). Methods of treating TNBC (pending to 2043). Methods of treating cancer (pending PCT to 2046). Treatment regimens (pending U.S. provisional to 2046).
  • In-licensed:
    • Takeda Pharmaceutical Company Limited: Non-exclusive license for a catalyst used in tovorafenib preparation.
    • MabCare Therapeutics: Exclusive worldwide license (ex-Greater China) for DAY301 composition of matter, methods of use, and synthetic intermediates (pending to 2044). Three patent families for ADC linker (pending to 2042).
• Licensing Programs: Ipsen Pharma SAS licensed ex-U.S. commercialization rights for tovorafenib.
• IP Litigation: No third-party patent infringement claims asserted as of December 31, 2025.

Technology Partnerships:

• Ipsen Pharma SAS: Exclusive license for ex-U.S. commercialization of tovorafenib.
• MabCare Therapeutics: Exclusive worldwide license (ex-Greater China) for DAY301.
• Foundation Medicine, Inc.: Collaboration for companion diagnostic assay for OJEMDA.
• Dana-Farber Cancer Institute / Pediatric Neuro-Oncology Consortium (PNOC): Collaborated on investigator-initiated Phase 1 trial for tovorafenib.
• Children’s Oncology Group: Collaborating on Phase 2 trial of tovorafenib in relapsed Langerhans cell histiocytosis.
• Pacific Pediatric Neuro-Oncology Consortium: Collaborating on Phase 2 trial of tovorafenib in craniopharyngioma.
• Hospital for Sick Kids (Toronto, Canada) / C17 Council: Collaborating on Phase 1/2 study of tovorafenib + vinblastine in relapsed/refractory low-grade glioma.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company is highly dependent on its executive officers and key employees. It has adopted a code of conduct and disclosure programs.

Board Composition: The Board of Directors, in coordination with the Audit Committee, oversees the company’s risk management program, including cybersecurity. The Board and Audit Committee receive regular presentations and reports on cybersecurity risks.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 178 full-time employees.
• Geographic Distribution: Approximately 20% at Brisbane, California headquarters, remaining working remotely.
• Skill Mix: 43 employees hold Ph.D., Pharm.D., or M.D. degrees; 90 engaged in research, development, and technical operations.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Adopted greater flexibility in recruiting practices to attract candidates outside the San Francisco Bay Area.
• Retention Metrics: Not explicitly disclosed, but the company aims to attract and retain qualified employees in a competitive industry with high turnover.
• Employee Value Proposition: Provides competitive compensation and benefits, and an incentive share plan to attract, retain, and motivate employees, consultants, and directors.

Diversity & Development:

• Diversity Metrics: Not explicitly disclosed, but the company is committed to creating and maintaining a diverse, inclusive, and safe work environment.
• Development Programs: Focuses on employee development, engagement, and diversity and inclusion.
• Culture & Engagement: Strives to foster long-term working relationships and has never experienced a work stoppage.

Environmental & Social Impact

Environmental Commitments: Not explicitly detailed in the provided text. Climate Strategy: Not explicitly detailed in the provided text. Supply Chain Sustainability: Not explicitly detailed in the provided text.

Social Impact Initiatives:

• Community Investment: Not explicitly detailed in the provided text.
• Product Impact: Dedicated to developing targeted therapies for people of all ages with life-threatening diseases, aiming to improve outcomes and life trajectories. Focus on pediatric patients addresses a significant unmet medical need.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed in the provided text.
• Economic Sensitivity: Not explicitly detailed in the provided text.
• Industry Cycles: Not explicitly detailed in the provided text.

Planning & Forecasting: Not explicitly detailed in the provided text.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• FDA Approval Process: Subject to extensive regulation by the FDA (FD&C Act) for research, development, testing, manufacturing, approval, labeling, promotion, and post-approval monitoring.
• Expedited Programs: OJEMDA received Breakthrough Therapy Designation and Rare Pediatric Disease Designation, leading to a Priority Review Voucher. The company may seek Fast Track, Breakthrough Therapy, or Priority Review for future candidates.
• Accelerated Approval: OJEMDA was approved under accelerated approval, requiring post-marketing confirmatory studies.
• Pediatric Regulations: Subject to Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) for pediatric studies and exclusivity.
• Companion Diagnostics: FDA approval/clearance required for companion diagnostics (e.g., FoundationOne CDx for OJEMDA).
• Post-Approval Requirements: Ongoing compliance with cGMPs, adverse event reporting, promotional restrictions, and potential REMS.
• International Compliance: Subject to varying regulatory requirements in foreign jurisdictions (e.g., EMA for Europe). Ipsen Pharma SAS is responsible for ex-U.S. regulatory activities for tovorafenib.

Trade & Export Controls:

• Export Restrictions: Subject to U.S. laws and regulations governing export controls, economic sanctions, and embargoes.
• Sanctions Compliance: Compliance with sanctioned entity restrictions and monitoring.

Legal Proceedings: Day One Biopharmaceuticals, Inc. is not subject to any material legal proceedings, and no material legal proceedings are currently pending or threatened as of December 31, 2025.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate (2025): 1.8% income tax benefit.
• Effective Tax Rate (2024): (8.1)% income tax expense.
• Rate Drivers (2025): U.S. federal statutory tax rate (21.0%), state and local income taxes (0.9%), tax credits (R&D: 2.8%, Orphan drug: 8.1%), changes in valuation allowances (-27.1%), nontaxable/nondeductible items (share-based compensation: -3.4%, unrecognized tax benefits: -0.6%), other adjustments (0.1%).
• Geographic Tax Planning: International tax structure and transfer pricing not explicitly detailed.
• Tax Reform Impact:
  • NOLs: Federal net operating loss (NOL) carryforwards of $261.6 million (do not expire) and federal tax credits of $39.6 million (expire starting 2041). State NOLs of $248.1 million (expire starting 2038) and state tax credits of $4.1 million (do not expire).
  • Section 382: Underwent an ownership change in an earlier year, but all tax attributes were fully available for use as of December 31, 2024. Future ownership changes may limit utilization.
  • R&E Expenses: Domestic R&E expenses allowed immediate deduction (electing two-year amortization). Foreign R&E expenses capitalized and amortized over 15 years.
  • Inflation Reduction Act (IRA): Imposed a 1% excise tax on certain stock repurchases (effective Jan 1, 2023).
  • One Big Beautiful Bill Act (OBBBA): Restored immediate deductibility of U.S. R&E expenditures after December 31, 2024.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains product liability insurance appropriate for its stage of development and cybersecurity insurance coverage subject to customary terms.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.
• Indemnification Agreements: Enters into contracts with indemnification provisions for certain liabilities and has indemnification obligations to directors and executive officers. No material claims to date.